Ocular Therapeutix
Ocular Therapeutix's revenue fell 18.5% to $52 million in fiscal 2025. Its operating margin was −519.8%, down from −269.6% a year earlier. Free cash flow was −$217 million. The diluted share count rose 18.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Ocular Therapeutix does
Ocular Therapeutix is a drug company focused on eye disease. It sells one approved product, DEXTENZA, a small insert placed in the tear duct that releases a corticosteroid. It is approved for eye inflammation and pain after eye surgery and for itching from allergic conjunctivitis.
Its main development program is AXPAXLI, an implant of the drug axitinib in a hydrogel that dissolves slowly in the eye. It is in Phase 3 trials for wet age-related macular degeneration, an eye disease of older adults, and for diabetic retinal disease. A second candidate, OTX-TIC, a travoprost implant for glaucoma, finished a Phase 2 trial, and Ocular says it is evaluating next steps. All of its products use its own hydrogel technology, called ELUTYX, to release a known drug over time.
Ocular earns revenue from DEXTENZA sales and has a history of losses. It has debt that it says may limit its cash flow.
Its biggest risks, as it describes them
- It has a history of losses and may never be profitable.
- It may need more funding, which could dilute shareholders or limit its operations.
- Its significant debt could limit cash it can invest in the business.
- Clinical trials of AXPAXLI could be delayed by slow enrollment or other unexpected events.
- Side effects found in trials could force it to limit or drop a program.
Income statement
Ocular Therapeutix lost money in fiscal 2025: a net loss of $266 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 164 | 102 | 196 | 392 | 737 |
| Debt incl. finance leases | — | 25 | 66 | 68 | 71 |
| Net debt (negative means net cash) | — | −77 | −130 | −324 | −666 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | 0.7x | 0.7x | 0.2x | 0.1x |
| Interest coverage | −11.7x | −11.2x | −7.3x | −12.7x | −22.8x |
| Current ratio | 7.3x | 4.1x | 6.7x | 10.7x | 15.4x |
| Quick ratio | 7.2x | 4.1x | 6.6x | 10.6x | 15.3x |
Cash flow
Projections
Project Ocular Therapeutix's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, 1 insider bought $461,354 of Ocular Therapeutix shares on the open market, and 6 insiders sold $2.8 million, $2.6 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 31, 2026 | Donald NotmanChief Operating Officer | Sold | 1,099 | $10.24 | $11,254 | Form 4 |
| Aug 24, 2026 | Pravin DugelSee Remarks, Director | Sold plan | 21,649 | $10.77 | $233,160 | Form 4 |
| Aug 24, 2026 | Jeffrey S. HeierChief Scientific Officer | Sold plan | 3,296 | $10.78 | $35,531 | Form 4 |
| Aug 24, 2026 | Peter KaiserChief Development Officer | Sold plan | 3,035 | $10.77 | $32,687 | Form 4 |
| Aug 24, 2026 | Sanjay NayakChief Strategy Officer | Sold plan | 1,897 | $10.78 | $20,450 | Form 4 |
| Jun 3, 2026 | Nadia WaheedChief Medical Officer | Sold plan | 14,828 | $8.27 | $122,628 | Form 4 |
| May 26, 2026 | Pravin DugelSee Remarks, Director | Sold plan | 21,156 | $8.20 | $173,479 | Form 4 |
| May 26, 2026 | Jeffrey S. HeierChief Scientific Officer | Sold plan | 3,018 | $8.20 | $24,748 | Form 4 |
| May 26, 2026 | Peter KaiserChief Development Officer | Sold plan | 2,967 | $8.20 | $24,329 | Form 4 |
| May 26, 2026 | Sanjay NayakChief Strategy Officer | Sold plan | 1,858 | $8.20 | $15,236 | Form 4 |
| Feb 23, 2026 | Pravin DugelSee Remarks, Director | Sold plan | 20,056 | $8.28 | $166,064 | Form 4 |
| Feb 23, 2026 | Jeffrey S. HeierChief Scientific Officer | Sold plan | 3,057 | $8.28 | $25,312 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 3 of 9 | 4 of 9 | 4 of 9 |
| Rule of 40 | −117.1% | −204.3% | −436.0% |
| Altman Z'' | −5.49 | −0.82 | 3.49 |
| Accruals ratio | −5.2% | −16.6% | −9.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Pass | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Pass | Fail | Fail |
| F-score | 3 of 9 | 4 of 9 | 4 of 9 |
Compare
Put Ocular Therapeutix side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Ocular Therapeutix | FY25 | −18.5% | −519.8% | −417.5% | — | — | 4 | |
| Agios Pharmaceuticals | FY25 | 48.0% | −873.9% | −698.3% | — | — | — | Compare |
| Nektar Therapeutics | FY25 | −43.9% | −253.7% | −377.8% | — | — | 2 | Compare |
| Aquestive Therapeutics | FY25 | −22.6% | −159.5% | −119.0% | — | — | 2 | Compare |
| Tango Therapeutics | FY25 | 48.3% | −178.4% | −224.3% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 2 | 2 | 2 | 4 | 17 | 44 | 52 | 58 | 64 | 52 |
| Revenue growth | 7.8% | 1.9% | 3.5% | 112.4% | 311.7% | 150.1% | 18.3% | 13.5% | 9.0% | −18.5% |
| Gross profit | 1 | 2 | 2 | 2 | 15 | 39 | 47 | 53 | 58 | 45 |
| Research and development | 27 | 31 | 37 | 41 | 29 | 50 | 54 | 61 | 128 | 197 |
| Operating income | −43 | −62 | −59 | −86 | −63 | −78 | −79 | −82 | −172 | −270 |
| Net income | −45 | −63 | −60 | −86 | −156 | −7 | −71 | −81 | −194 | −266 |
| Diluted EPS (US$) | −1.80 | −2.20 | −1.57 | −1.91 | −2.56 | −0.98 | −0.97 | −1.02 | −1.22 | −1.42 |
| Diluted shares (millions) | 25 | 29 | 38 | 45 | 61 | 82 | 83 | 86 | 158 | 187 |
| Cash flow | ||||||||||
| Cash from operations | −34 | −50 | −49 | −78 | −54 | −66 | −60 | −70 | −135 | −205 |
| Capital expenditure | 2 | 8 | 2 | 2 | 1 | 1 | 4 | 6 | 1 | 12 |
| Free cash flow | −36 | −59 | −51 | −80 | −54 | −67 | −63 | −76 | −136 | −217 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 6 | 7 | 8 | 9 | 8 | 15 | 17 | 18 | 33 | 43 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 68 | — | 54 | 54 | 228 | 164 | 102 | 196 | 392 | 737 |
| Debt incl. finance leases | 16 | 18 | — | 25 | 25 | — | 25 | 66 | 68 | 71 |
| Total assets | 75 | 55 | 73 | 79 | 262 | 205 | 149 | 252 | 458 | 808 |
| Total liabilities | 23 | 29 | 37 | 82 | 186 | 117 | 114 | 161 | 143 | 154 |
| Shareholders' equity | 52 | 26 | 36 | −4 | 76 | 88 | 35 | 91 | 315 | 654 |
| Margins and ratios | ||||||||||
| Gross margin | 76.5% | 76.2% | 76.6% | 45.0% | 88.0% | 89.9% | 91.2% | 91.0% | 91.2% | 87.3% |
| Operating margin | −2,296.0% | −3,220.1% | −2,970.8% | −2,029.9% | −361.1% | −179.3% | −152.7% | −141.0% | −269.6% | −519.8% |
| Net margin | −2,369.0% | −3,296.2% | −3,014.0% | −2,043.3% | −894.3% | −15.1% | −137.9% | −138.1% | −303.7% | −511.9% |
| Free cash flow margin | −1,903.5% | −3,053.8% | −2,568.6% | −1,888.2% | −312.6% | −153.4% | −123.0% | −130.6% | −213.4% | −417.5% |
| Rule of 40 (growth + FCF margin) | −1,895.7% | −3,051.9% | −2,565.2% | −1,775.8% | −0.8% | −3.3% | −104.6% | −117.1% | −204.3% | −436.0% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −63.1% | −162.2% | −193.4% | −535.7% | −429.6% | −8.0% | −115.2% | −127.6% | −95.2% | −54.9% |
| Return on assets | −48.3% | −97.2% | −93.4% | −113.8% | −91.4% | −2.8% | −40.1% | −40.2% | −54.5% | −42.0% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |